Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIG-DICA: Digoxin in Heart Failure After Acute Decompensation
NCT07321509Phase 4Recruiting
- Sponsor
- Hospital Argerich
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of digoxin in Acute Heart Failure (AHF) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Hospital Argerich. Primary endpoint: Proportion of participants who are 'well and alive' (alive and with quality-of-life score >=75) at 180 days. Started Dec 2025; status: recruiting.
02
Drugs
digoxin
03
Conditions
Acute Heart Failure (AHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07321509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321509.